Most antibiotics used in human medicine originate from natural products derived from bacteria and other microbes. Novel microorganisms are therefore a promising source of new active compounds - also for the treatment of diseases such as cancer or viral infections. A team from the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now been able to isolate a completely new family of bacteria that has particularly high potential for the production of active substances. The researchers published their findings in the journal Chem.

A team led by Prof. Achim Hoerauf, University Hospital Bonn (UKB), in cooperation with the University of Bonn and the Helmholtz Centre for Infection Research (HZI), is developing the antibiotic corallopyronin A (CorA) as a treatment for the neglected tropical diseases river blindness and lymphatic filariasis. They have now succeeded to enter into a partnership with the Japanese pharmaceutical company Eisai and to raise a large amount of funding. The team's aim is to develop a safe and sustainably effective drug against these worm diseases, which are transmitted to humans by mosquitoes. The people affected mainly live in Africa and tropical regions and urgently need active ingredients that kill the long-lived adult worms. The project is now being funded with around €5.6 million by the Japanese Global Health Innovative Technology (GHIT) Fund.

Lyme disease is the most common disease transmitted by tick bites in Germany. Whether a particular genetic predisposition plays a role in the development of the disease and which immunological processes in the body are involved is not yet sufficiently understood. A research team from the Centre for Individualised Infection Medicine (CiiM), a joint institution of the Helmholtz Centre for Infection Research (HZI) and Hannover Medical School (MHH), has now discovered a responsible gene variant and the immune parameters involved in cooperation with Radboud University Hospital (Radboundumc; Radboud Universitair Medisch Centrum) and Amsterdam UMC (both in the Netherlands). The researchers have published their findings in two studies. These have been published in the journal Nature Communications and BMC Infectious Diseases.